FibroBiologics Inc. held a special meeting of stockholders on February 20, 2026. Stockholders approved an amendment to the certificate of incorporation to authorize a reverse stock split of issued and outstanding common stock and preferred stock within a board-selected range. Stockholders also approved the issuance of common stock upon exercise of outstanding common warrants tied to a November 18, 2025 securities purchase agreement, approved additional warrant-related share issuances tied to November 24, 2025 securities purchase agreements and a related engagement letter, approved additional warrant-related share issuances tied to December 14, 2025 securities purchase agreements and a related engagement letter, and approved the adjournment of the meeting if needed to solicit additional votes or establish a quorum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-064040), on February 23, 2026, and is solely responsible for the information contained therein.